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ABSTRACT
Osteoarthritis is one of the leading causes of lameness in the athletic horse.
Cases of equine osteoarthritis typically present with synovitis, or inflammation of
the synovium. This inflammation in the synovium leads to the production of
inflammatory cytokines and eicosanoids. Although these downstream products can
be beneficial, overproduction can lead to degradation of cartilage and joint disease.
Opportunities to help mitigate or decrease inflammation within the joint are of
current interest to the equine industry. One method being investigated is
nutritional supplementation. The anti-inflammatory effects demonstrated by CLA
supplementation make it a potential prospect for utilization in mitigating joint
inflammation. Therefore, this in-vitro study was designed to measure COX-2
expression in rabbit fibroblastic synoviocytes when challenged with LPS and
pretreated with CLA (cis-9, trans-11 and trans-10, cis-12 isomer mixture). Results of
this study demonstrated a significant increase in COX-2 production when both CLA
and the LPS were added to the cell cultures. This increase in mRNA expression
suggests there is possibly a different mechanism through which the CLA is acting
upon in the synovioctye or the effects of the LPS challenge may be causing down
regulation of a protein receptor involved in CLA’s anti-inflammatory mechanism.
Results of this study display the need for further research to determine the specific
effects of the different CLA isomers on the synovium. In addition, investigating the
mechanism by which the CLA isomers influences joint inflammation through their
action on the synoviocytes needs to be investigated further.
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CHAPTER ONE
INTRODUCTION

The production of regulatory proteins, cytokines, and eicosanoids within the
joint is beneficial in appropriate amounts; however, overproduction can have
detrimental effects. In fact, overproduction has been tied to inflammatory
conditions, such as osteoarthritis. Osteoarthritis (OA) is one of the primary causes of
disuse within the performance horse industry.
Multiple epidemiological studies have identified lameness as a primary cause
of disuse and loss of training days in Thoroughbred racehorses (Dyson et al., 2008;
Jeffcott et al., 1982; Lindner and Dingerkus, 1993; Rossdale et al., 1985; Wilsher et
al., 2006) and horses involved in other disciplines (Dabareiner et al., 2005a, b;
Dyson, 2000; Jackman, 2001). Joint injury and disease have been shown to be the
most common cause of lameness (McIlwraith, 1996; Preston et al.,2008; Neundorf et
al., 2010), and may eventually lead to early retirement or disuse in today’s sport
horse.
Costs for effective diagnostics, treatment, medication, and management of
degenerative joint disease or OA in the horse increase quickly. In 2010, Dr. Stacey
Oke and Dr. Wayne McIlwraith outlined both the direct and indirect costs associated
with the disease. Direct costs, being the more easily measured, include any fees
associated with both the diagnostics and treatment. Approximate direct costs
associated with OA are about $3,000 annually per case. Although indirect costs are
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more difficult to measure, if included, expenses increase significantly, with costs
reaching up to $15,000 per case (Oke et al., 2010). Indirect costs may include the
loss of employment and performance horse income; in addition to the horse’s
reduced abilities and an increased workload for the primary caregiver (Oke et al.,
2010).
Lameness caused by joint disease was first noted as a critical cause of
disability in the equine in 1938 (Callender and Kelser, 1938). Researchers at that
time noted the positive correlation between an individual’s activity expected and
disease susceptibility. The performance horse is repeatedly subjected to
biomechanical stresses of abnormal intensity, duration, and frequency resulting in
more frequent joint injuries (Pool, 1996). With the demanding expectations and
rigorous training schedules, performance horses are likely candidates for lameness
and joint disease (Reed et al., 2012). Ultimately, an inability to perform due to
lameness, leads to the wastage of performance horses; thus causing substantial
economic loss in the industry (Jeffcott et al., 1982; Harst et al., 2005; Wilsher et al.,
2006). Justifiably, the value of a horse is dependent upon its ability to meet or
exceed its athletic expectations.
Although sport horses are most often affected, lameness caused by joint
injury impacts equine operations of all types. A national survey conducted in 2000
reported that 50% of all equine operations housing three or more horses have at
minimum one horse become lame annually (Kane et al., 2000). As expected,
boarding and training facilities’ incidence of lameness is greater than that of other
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equine operations (Kane et al., 2000). Joint issues are a prevalent concern for the
entire equine industry; thus a thorough understanding of the joints affected and
OA’s progression is of the utmost importance as it can aid in the development of
methods to prevent its manifestation. Modification to the animal’s diet via
nutritional supplementation, as an arthritis preventative, is a current method of
approach. Research thus far has focused on glucosamine, omega-3, and chondroitin
sulfate supplementation; however, little research has investigated the effects of
conjugated linoleic acid (CLA) supplementation. Many studies have used models
with existing OA problems rather than using supplementation as a preventative
strategy.
Recent studies have demonstrated CLA’s anti-inflammatory properties, thus
making it a possible candidate for arthritis prevention in the horse. When
supplemented with dietary CLA in a systemic lipopolysaccharide (LPS) challenged
model, lower circulating levels of tumor necrosis factor-α (TNF-α) were observed in
weanling barrows (Changhua et al., 2005). Despite CLA’s ability to decrease
cytokine profiles in the pig, further research is needed to fully uncover the potential
of CLA supplementation and its effect on joint inflammation.
This in-vitro study has been designed to further analyze CLA’s effects in a LPS
acute inflammatory-induced model. The goal is to determine if CLA will decrease
inflammatory mediators within the joint and/or exert an effect on hyaluronan
degradation and synthesis. The results generated will assist in determining if CLA

3

supplementation is an effective method for reducing joint inflammation,
degradation, and possibly the incidence of OA.
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CHAPTER TWO
LITERATURE REVIEW

Synovial Joint Anatomy
The synovial, or articular, joint is designed for two main purposes: motion
and load transfer between bones (Todhunter, 1996). Function follows form;
therefore, in order to facilitate these major functions, the synovial joint has unique
anatomical features. Located between at least two long bones, the synovial joints
consist of cartilaginous, osseous, synovial, and fibrous tissues (Pool, 1996). The
tissues of the joint are all subjected to the biomechanical stresses involved in
performance and training; however, only bone tissue is capable of complete repair
and able to undergo remodeling to better accommodate the stresses of athletic
activity (Pool, 1996).
Articular Cartilage
The synovial joint’s primary feature is the thin protective layer of hyaline
articular cartilage at the end of each bone (Todhunter, 1996). This smooth glasslike
layer provides a lubricated, frictionless surface allowing for fluid and easy motion
(Kheir and Shaw, 2009). Hyaline cartilage is avascular and aneural; therefore, when
damaged or lost, repair or replacement is unlikely (Kheir and Shaw, 2009). The
inability to repair may cause damaged hyaline cartilage to be replaced by
fibrocartilage (Pool, 1996). In comparison to normal articular cartilage, which
consists of approximately 85-90% type II collagen (Todhunter, 1996), fibrocartilage
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is mechanically and biochemically substandard due to high collagen type I content
(Furukawa et al., 1980). Type II collagen is thought to provide tensile strength.
Normal, healthy, adult cartilage is approximately 70% water; however, on a dry
weight basis, hyaline cartilage is comprised of: 50% collagen, 35% proteoglycans,
10% glycoproteins, 3% mineral, 1% lipid, and 1-12% chondrocytes (Todhunter,
1996). The proteoglycans making up the extracellular matrix are hyaluronan,
chondroitin sulfate, and keratin sulfate. These positively charged sugars
(chondroitin sulfate and keratin sulfate) attach to hyaluronan and attract water into
the joint, giving it compressive strength. Although only representative of a small
percentage, the cellular component of articular cartilage, chondrocytes, plays a vital
role in maintaining articular cartilage homeostasis. Each chondrocyte is located in
lacunae, where it secretes and regulates the extracellular matrix (Todhunter, 1996).
Due to their avascular nature, the chondrocytes receive nutrients though diffusion,
therefore they are highly dependent upon the fluid for nutrient availability. The
fluid movement in and out of the cartilage is facilitated by joint use and bathes the
chondrocytes with nutrients. The cartilage matrix turnover, predominately made
up of collagen, more specifically type II collagen, is slow when compared to
proteoglycan turnover (Kheir and Shaw, 2009). Each component of articular
cartilage contributes by maintaining cartilage homeostasis and proper joint function
(Mueller and Tuan, 2011).
Synovium
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Two specific layers form the articular joint capsule, each of which contribute
to the integrity of the joint in a specific way. The two layers are the fibrous joint
capsule and the synovial membrane (Palmer and Bertone, 1994). The fibrous joint
capsule utilizes a network of elastic fibers and connective tissue to stabilize the joint
(Palmer and Bertone, 1994). Physiologically, the membrane is highly vascularized
and responsible for providing nutrients and nourishment to the chondrocytes
through the synovial fluid (Sellam and Berenbaum, 2010). The synovial membrane
of the articular joint capsule consists of two layers of modified mesenchyme:
subintiam and intima (Palmer and Bertone, 1994; Todhunter, 1996). Depending on
the location inside the joint, the connective tissue layer or the subintiam may be
fibrous, areolar, or adipose (Palmer and Bertone, 1994; Todhunter, 1996). Located
between the subintiam and the synovial fluid, the intima layer is comprised of
synoviocytes. This layer lacks a basement membrane and ranges from one to four
cells in thickness (Todhunter, 1996). The barrier provided by the membrane, allows
for the ultrafiltration of plasma (Todhunter, 1996). The combination of utrafiltrate
plasma and synoviocyte secretions determines the synovial fluid composition
(Todhunter, 1996).
The cellular component of the synovium, the synoviocytes, maintain a high
level of metabolic activity (Sellam and Berenbaum, 2010) and are noted to have
both secretory and phagocytic properties (Palmer and Bertone, 1994; Todhunter,
1996). It is generally accepted that synoviocytes can be classified into two main
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types: Type A and Type B (Iwanaga et al., 2000). A third intermediate or
transitional type has also been identified (Iwanaga et al., 2000).
The two main types were initially identified by their difference in
morphology, but are now additionally thought to fulfill different physiological roles.
The Type A synoviocytes are round and act as resident macrophages (Iwanaga et al.,
2000). These cells are located in the upper portion of the intima with cell surface
receptors, which suggest a role in immunological and inflammatory responses
(Iwanaga et al., 2000). The function of Type A synoviocytes has been further
established than that of Type B synoviocytes. Type B synoviocytes are known to be
fibroblastic cells (Iwanaga et al., 2000). These fibroblastic cells comprise the
majority of the synovial cell lining (Iwanaga et al., 2000; Palmer and Bertone, 1994).
Unlike Type A cells, Type B cells have rough endoplasmic reticulum scattered
throughout the cytoplasm (Wilkinson et al., 1992). The abundance of rough
endoplasmic reticulum in these cells suggests an active role in protein synthesis,
thus Type B cells are thought to be responsible for the secretion of hyaluronan into
the synovial fluid (Iwanaga et al., 2000).

Synovial Fluid
Synovial fluid fills the intra-articular joint space between the synovial lining
and the articular cartilage. This viscous fluid serves many essential functions within
the joint such as nourishment, waste removal, and lubrication (Todhunter, 1996).
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Due to the avascular nature of cartilage, chondrocytes rely heavily on
synovial fluid to supply them with the nutrients they require for proper function.
Most ions and solutes found in synovial fluid are present in blood plasma; therefore,
the concentration of nutrients present is determined by plasma’s filtration through
the synovial lining (Todhunter, 1996). The exchange of fluid simultaneously
facilitates an influx of nutrients and removes waste products produced by the joint;
the exchange is driven by the differences in hydraulic, hydrostatic, and colloid
osmotic pressure (Todhunter, 1996).
In addition to the ultra-filtrate of plasma, synovial fluid contains
glycoproteins and hyaluronan. The molecular composition of synovial fluid enables
its function as both a biomechanical lubricant and a shock-absorbing barrier. By
reducing friction within the joint, it assists in maintaining the integrity of both the
synovial lining and the articular cartilage (Todhunter, 1996).

Hyaluronan
Hyaluronan is considered a macromolecule and can reach up to several
million Daltons in size (Tamer, 2013). Hyaluronan is recognized for both its
rheological properties (Bothner and Wik, 1987; Gibbs et al., 1968) and its
magnitude for binding up to 1000 times its own weight in water (Jiang et al., 2007).
As a result, hyaluronan solutions are extremely hydrophilic and viscous (Jiang et al.,
2007; Tamer, 2013). These attributes make hyaluronan the primary lubricating
molecule in synovial fluid. Chain length directly influences viscosity and water
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binding capacity (Noble, 2002); therefore, high molecular weight (HMW)
hyaluronan is the predominate molecule in the synovial fluid. The average size of
HMW hyaluronan is about 6-7 x 106 Daltons (Yoshida et al., 2004).
Hyaluronan belongs to a family of polysaccharides known as
glycosaminoglycans (Bastow et al., 2008; Jiang et al., 2007). Most
glycosaminoglycans are synthesized in the Golgi apparatus, where sulfates can be
added to the protein core. Hyaluronan is unique because this addition is
unnecessary for polymerization (Bastow et al., 2008). As a result, synthesis occurs
at the plasma membrane and the molecule remains un-sulfated (Prehm, 1983;
Weigel et al., 1997; Itano and Kimata, 2002).
As the hyaluronan chain grows in size, a trans-membrane protein facilitates
its extrusion into the extracellular space allowing it to reach such large molecular
weights (Hiscock et al., 2000). The enzyme responsible for hyaluronan synthesis,
hyaluronan synthase (HAS), is located on the internal side of the plasma membrane
(Weigel et al., 1997). This enzyme has three isoforms: HAS1, HAS2, and HAS3. Each
enzyme, although similar in sequence and structure, maintains distinct enzymatic
properties (Itano and Kimata, 2002; Itano et al., 1999). The most notable difference
between these enzymes is the chain length synthesized (Itano et al., 1999). The
HAS1, HAS2, and HAS3 produce hyaluronan with an average molecular mass
ranging from 2 × 105 to 2 ×106 Da, 2×106 Da, 1×105 to 1×106 Da, respectively
(Itano and Kimata, 2002).
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The degradation of hyaluronan in vivo is contributed to oxygen free radicals
(Schiller et al., 2003) and hyaluronidase (Chow et al., 2006). Hyaluronidase (HYAL)
is responsible for catalyzing hyaluronan degradation through hydrolysis of
hyaluronan’s β (1-4) linkages (Tanimoto et al., 2001). In some cases, attached
glycosaminoglycans, like chondroitin sulfate, will also be broken down (Bastow et
al., 2008). The majority of circulating hyaluronan is degraded by endocytosis in the
lymph nodes and the liver; however, hyaluronan in cartilage and bone is stationary
and inaccessible to the lymphatic system (Bastow et al., 2008). As a result,
hyaluronan is degraded locally. Lysosomes containing hyaluronidases and
exoglycosidases engulf hyaluronan for its degradation (Bastow et al., 2008). Several
different HYAL genes have been identified in the human: HYAL1, HYAL2, HYAL3,
HYAL4, HYALP1 and PH-20 (Csoka et al., 2001). The two main forms of
hyaluronidase, HYAL1 and HYAL2, are thought to have a wide distribution across
mammalian tissues (Csoka et al., 2001; Tanimoto et al., 2001); the mechanisms
responsible for alterations in HYAL1 and HYAL2 expression are still widely
unknown.
HASs and HYALs in the synovial joint
In inflammatory joint disease both the molecular mass and concentration of
synovial fluid hyaluronan decreases (Pitsillides et al., 1994). Maintenance of
hyaluronan size and concentration in synovial fluid is highly important, as a
reduction in either will result in a decreased viscosity and can lead to cartilage
damage (Pitsillides et al., 1994). Hyaluronan is secreted into the synovial fluid by
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the fibroblastic synoviocytes. The primary synthases expressed in human synovium
are HAS1 and HAS2 (Bastow et al., 2008; Ohno et al., 2001; Recklies et al., 2001).
Inflammatory conditions, such as arthritis, cause a decrease in expression of HAS1
and HAS2 (Yoshida et al., 2004). Healthy synovial fluid maintains a predominating
concentration of HMW hyaluronan. The enzyme, HYAL2, causes its degradation into
smaller molecular weight fragments of approximately 20 kDa (Lepperdinger et al.,
2001; Tanimoto et al., 2001). Yoshida et al. (2004) reported an increase of HYAL2
expression in the synovial fluid of arthritic knees in comparison to synovial fluid
aspirated from healthy patients; thus the decrease in the molecular weight of
hyaluronan in inflammatory conditions may be due to an increase in HYAL2’s
activity.

Osteoarthritis and Inflammation
Osteoarthritis (OA) is specific to synovial or articular joints and is
characterized by progressive or permanent cartilage degradation (Pool, 1996) and
causes lameness and debilitation for humans and horses. Cartilage damage caused
by OA can range from localized splitting and fibrillation to dissolution or complete
loss in the articular joint (McIlwraith, 1996). Dr. Wayne McIlwraith originally
classified OA in the horse into 5 categories. He further modified those classes in
1996 by condensing them into 3 categories (Table 1; McIlwraith, 1996).
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TABLE 1: Classification of Osteoarthritis in the Horse (McIlwraith, 1996)
Classification of Osteoarthritis in the Horse (McIlwraith, 1996)
Type 1

Directly associated with synovitis and capsulitis

Type 2

Arthritis secondary to previously identified injuries, including but not limited to: intraarticular fractures, traumatic articular cartilage ligamentous injuries, osteochondrosis,
or septic arthritis

Type 3

Articular cartilage erosion that is minor or non-progressive

These three categories are still referred to today. In some cases the induction
of joint inflammation is caused by a clearly defined injury; however, this is not
always the case. Inflammatory conditions often result from repetitive trauma; this
is referred to as ‘use-trauma’ (Kidd et al., 2001). Due to involvement of
inflammatory conditions, Type 1 is of particular interest to the current study. Type
1 typically affects high locomotion joints such as the carpus, fetlock, distal tarsal,
and the distal interphalangeal (McIlwraith, 1996). This classification of OA develops
from trauma-induced synovitis or capsulitis (McIlwraith, 1996) and is present in the
majority of equine OA cases. This presence of synovitis has now been recognized as
a clinical symptom in human OA; this similarity demonstrates that the horse is a
good model of naturally occurring OA (McIlwraith et al., 2012).
Synovitis, or inflammation of the synovium, is directly related to many of the
clinical symptoms of OA and is indicative of the disease’s structural progression.
Localized signs of inflammation along with effusion and palpable joint swelling are
associated with synovitis (Krasnokutsky et al., 2008; Sellam and Berenbaum, 2010).
This presence of inflammation causes altered cartilage metabolism by decreasing
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anabolic activity and increasing catabolic activity (Kidd et al., 2001). The integrity
of articular cartilage is heavily dependent on maintaining a balance of anabolic and
catabolic activity within the joint (Mueller and Tuan, 2011). Inflammatory
mediators, or cytokines, are integrally involved in synovitis and can be detected and
measured in the synovial fluid. These mediators can originate from 3 different
tissues: cartilage, subchondral bone, and the synovium (Sellam and Berenbaum,
2010).
The anatomical features that define articular joints predispose the joint to
the onset of OA and are often instrumental in the development and progression of
the disease (Goodrich and Nixon, 2006). As a built-in defense mechanism, the body
naturally produces cytokines. Cytokines are non-antibody proteins that act as
mediators between cells that play a critical role in immunoregulation. Cytokines are
produced by monocytes and macrophages and are part of the innate immune
system. A few cytokines that are integral players in the inflammatory response are
interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α).
These cytokines mediate systemic effects of inflammation causing fever, loss of
appetite, protein and fat mobilization, and acute phase protein synthesis
(McIlwraith, 1996). While production of these cytokines is a beneficial part of the
innate immune system, chronic inflammation often leads to an overproduction of
these factors (Fernandes et al., 2002). The body utilizes growth factors to down
regulate cytokine production. When the cytokines are overproduced, the growth
factors are unable to keep up and other anti-inflammatory cytokines are
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insufficiently released (Fernandes et al., 2002). Overproduction has been tied to the
pathological responses to inflammatory conditions, such as arthritis (Grimble,
1998).
Synovial fibroblasts maintain a high concentration of IL-1β and TNF
receptors (Sadouk et al., 1995; Sellam and Berenbaum, 2010) these cytokines are
capable of self-stimulation through an autocrine mechanism. This autocatalytic
effect stimulates, not only the continued production of IL-1β and TNF, but also
initiates production of other cytokines (IL-6, IL-8, leukocyte inhibitory factor),
ecoisinoids, and matrix metalloproteases by the synoviocytes and chondrocytes
(Sellam and Berenbaum, 2010).
Eicosanoids are synthesized from arachadonic acid (AA) present in cellular
membrane phospholipids. The eicosanoid cascade is driven by the action of multiple
enzymes. The downstream product, prostaglandin E2 (PGE2), is produced in
inflamed joints and is associated with joint disease (Frisbie et al., 2008). In addition
to increasing pain and vasodilation of the joint, PGE2 degrades and inhibits synthesis
of proteoglycan in the cartilage (Fernandes et al., 2002; Martel-Pelletier et al., 2003).
The enzyme, cyclooxygenase (COX), which has two forms, regulates its production
of COX-1 and COX-2. The constitutively expressed form COX-1 is often considered a
housekeeping enzyme that is involved in homeostatic physiological processes
(Martel-Pelletier et al., 2003; McIlwraith et al., 2012). Alternatively, COX-2 is the
enzyme’s inducible form that is associated with inflammatory conditions and OA
(Martel-Pelletier et al., 2003). Bacterial lipopolysaccharides and cytokines can
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stimulate COX-2, which leads to PGE2 production causing both the induction and
maintenance of inflammation (Figure 1).
The bacterial endotoxin, LPS, has been shown to produce a localized
inflammatory response in-vivo (Lucia et al., 2013) and in-vitro (Rietschel et al.,
1994) and is often used as an inflammatory inducer in research studies. The
mechanism of action for LPS does not typically induce toxic effects because it
requires an active response by the host cells (Rietschel et al., 1994). Activation of
macrophages by LPS leads to the production of cytokines such as TNF-α, IL-β, and
IL-6 (Rietschel et al., 1994) by eliciting the localized inflammatory response.

16

Cox-2

FIGURE 1: Arachadonic acid cascade

Mitigating Inflammation
Current Methods
Multiple methods currently exist for mitigating inflammation within the joint,
one of which is the use of nonsteroidal
onsteroidal anti
anti-inflammatory
inflammatory drugs (NSAIDs).
(NSAIDs) Any
nonsteroidal drug may be encompassed in this category; however, it is most
commonly related to NSAIDs that influence eicosanoid production. Most NSAIDs
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exert an inhibitory effect on the COX enzyme to some extent; however, some affect
one form of the enzyme more than the other. NSAIDs have been utilized in the
treatment of the pain involved in joint disease and OA for many years and can be
administered intravenous (IV) and orally (McIlwraith, 2010). Although effective in
reducing clinical signs during treatment, discontinued treatment has revealed the
reappearance of symptoms. Administrations of NSAIDs are needed on a regular
basis to prevent symptoms from returning. Possible adverse effects such as gastric
ulcers in athletic horses are a cause for concern and need for alternative methods.
Oral joint supplements such as glucosamine and/or chondroitin sulfate have
shown promise; however, commercially available supplements are unregulated by
the FDA because they are marketed as neutraceuticals (Neil et al., 2005). This lack
of regulation has led to commercially available products with little research to
support them and often vary in purity and quality (Neil et al., 2005).
Conjugated Linoleic Acid
Conjugated linoleic acids (C18:2; CLA) are the positional and geometric
isomers of linoleic acid that contain conjugated double bonds (Figure 2; Pariza et al.,
2001). Twenty-eight different isomers have been identified (Pariza et al., 2001).
The main isomers are the cis-9, trans-11 and the trans-10, cis-12 isomers. Between
these the predominant isomer is the cis-9, trans-11 which accounts for
approximately 90% of dietary CLA sources, and the trans-10, cis-12 isomer accounts
for 1 -10% (Pariza et al., 2001).
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Trans-10, Cis-12
CLA

Cis-9,
9, Trans-11
Trans
CLA

Linoleic Acid

FIGURE 2: Conjugated linoleic acid structures; adapted from Pariza et al., 2001.
2001

Research has shown CLA to have numerous biological and physiological
effects (Pariza et al., 2001) including
including, but not limited to: anti-inflammatory
inflammatory effects in
pigs (Zhao et al., 2005),, anti
anti-carcinogenic effects in rodent models (Ip
Ip et al., 1991;
Lavillonniere et al., 2003), and ability to alleviate the inflammation-associated
associated
diseases (Bassaganya-Riera
Riera et al., 2004
2004). Together the trans-10, cis-12
12 and the cis-9,
cis
trans-11 isomers are the main isomers of CLA utilized in synthetic supplements.
supplement
Research continues to show that the biological effects associated with CLA are due
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to distinct actions by either the cis-9, trans-11 or trans-10, cis-12 isomers (Pariza et
al., 2001). Responses may also be initiated and/or increased through the synergistic
actions of both isomers (Pariza et al., 2001).
Investigation of CLA supplementation’s effect on in-vivo cytokine production
has revealed CLA’s anti-inflammatory properties. Utilizing LPS to induce an acute
systemic inflammatory response, weaned pigs fed a 2% CLA supplemented diet had
lower levels of TNF-α (Changhua et al., 2005). Changhua and colleagues (2005) also
showed that the trans-10, cis-12 isomer decreased LPS induced TNF-α more so than
the cis-9, trans-11 CLA isomer (Changhua et al., 2005). Lowered circulating PGE2
levels were found in CLA-supplemented pigs. Observed levels of plasma IL-6 and
TNF-α decreased in LPS-challenged pigs fed CLA after 2 injections of LPS, indicating
CLA may have a greater effect over time. Zhao et al, (2005) found similar results,
with the trans-10, cis-12 CLA isomer decreasing production and expression of TNFα, while other research has shown the trans-10, cis-12 isomer to be
proinflammatory (Yu et al., 2002).
Despite CLA’s ability to decrease cytokine profiles in the pig, further research
is needed to fully uncover the potential of CLA supplementation and its effect on
joint inflammation. At this point there is limited research examining the effects of
CLA supplementation in horses and in the synovial joint. In 2012, a study was
performed at Clemson University that determined the bioavailability of CLA when
fed to horses and its effect on plasma fatty acid profiles. When fed CLA at an
inclusion rate of 0.0055% BW, plasma CLA concentration increased, while

20

arachidonic acid (C20:4) decreased (Headley et al., 2012). The effect of CLA alone
and in combination with other polyunsaturated fatty acids (PUFAs) has been
examined in human osteoarthritic chondrocytes. Shen and colleagues (2004) found
that CLA decreased the PGE2 production in osteoarthritic human chondrocytes. The
bioavailability of CLA in the horse, in addition to its chondro-protective actions in

cartilage metabolism, demonstrates CLA’s potential as a nutritional joint
supplement.
Summary and Goals of Current Study
Synovitis has been recognized as a primary clinical symptom in patients with
OA and most equine cases present with synovitis (McIlwriath et al., 2012). This
inflammation within the synovium can ultimately cause a chain of events that lead
to cartilage and matrix degradation. Traumatic synovitis causes normal stress on
abnormal cartilage leading to the enzymatic breakdown of articular cartilage
components: proteoglycans and collagen (McIlwraith, 1996). Acute synovitis and
capsulitis cause swelling, pain, and initiate production of enzymes, inflammatory
mediators, and cytokines by the fibroblastic synoviocytes (Type B). Additionally, the
production of prostaglandins is increased within inflamed joints. Although, the
production of regulatory proteins, cytokines, and eicosanoids within the joint is
beneficial in appropriate amounts, overproduction can have detrimental effects.
Prostaglandin, more specifically PGE2, negatively affects proteoglycan
synthesis in articular cartilage, in addition to increasing degradation. Pain
perception is also associated with PGE2. The enzyme responsible for PGE2
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production is the COX enzyme. This enzyme exits in two forms: COX-1 and COX-2.
The form most commonly associated with synovitis and inflammation is COX-2.
Prostaglandins are derived from AA, which is present in phospholipid membranes.
In order to decrease the incidence of OA, the mitigation of the inflammatory
response of the joint may prove to have chondroprotective effects. If nutritional
avenues are used, it is important to recognize the bioavailability of the supplement,
and its effects on the target cells.
Limited research has investigated the effects of CLA supplementation on joint
inflammation; however, studies have demonstrated CLA’s anti-inflammatory
properties. These properties make it a possible candidate for arthritis prevention.
When supplemented with CLA in a LPS-challenged model, lower circulating levels of
tumor necrosis factor-α (TNF-α) were observed in weanling barrows (L. Changhua,
et al. 2005). Despite CLA’s ability to decrease cytokine profiles in the pig, further
research is needed to uncover the potential of CLA supplementation and its effect on
joint inflammation. The anti-inflammatory properties and bioavailability of CLA in
mammals (Headley et al., 2012) makes dietary CLA supplementation a possible
option for preventing chronic inflammation in equine joints.
Due to the highly vascularized nature of the synovium, biologically available
CLA will have the opportunity to exert its affect on the fibroblastic synoviocytes
before it reaches the articular cartilage. There are no studies, to which I am aware,
testing CLA’s effects on the fibroblastic synoviocytes. Therefore, this study was
designed as a preliminary study to examine what effect CLA has on COX-2
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expression in fibroblastic synoviocytes. We also investigated how synoviocyte pretreatment with CLA would affect COX-2 expression in an inflammatory-challenged
model utilizing LPS.
The objective of the current study was to utilize an in-vitro model to measure
the effect of CLA as a protectant against LPS-induced inflammation in articular
synoviocytes. Cells will be pre-treated with CLA prior to an inflammatory insult by
LPS. The expression of Cox-2 will be evaluated. Both HAS2 and HYAL2 were
potential response variables for this study; however, inadequate primer sequences
led to their elimination. The effect of CLA on hyaluronan synthesis and degradation
in the synoviocytes is still a question needing exploration. The results generated will
assist in determining if CLA supplementation is effective at reducing localized joint
inflammation.
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CHAPTER 3
MATERIALS & METHODS
Experimental Design
This study was designed to examine the effects of a cis-9, trans-11 and trans10, cis-12 isomer mixture CLA supplement (>99% purity isomeric mixture; ~50:50
isomer ratio; Nu-Check-Prep, Elysian, MN) on rabbit articular fibroblastic
synoviocytes in an LPS-inflammatory induced model. The LPS was derived from
Escherichia coli serotype O55:B5 (Sigma-Aldrich, St. Louis, MO). Synoviocytes were
pretreated with CLA for 24 h, prior to the induction of an inflammatory insult by
LPS. A randomized complete block design with a 2 x 2 factorial treatment structure
was used to evaluate the effects of both CLA and LPS on the synoviocytes.
Treatment groups were as follows: control, CLA only, LPS only, and CLA + LPS. All
four treatments were applied to a plate (Figure 3), which served as the block. The
total sample size for this study is n=20 with n=5 in each treatment group.
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Figure 3: HIG-82 Treatment groups

Cell Culture
Rabbit synoviocytes, cell line HIG-82 (ATCC CRL-1832), were purchased
from American Type Culture Collection (Manassas, VA, USA). Frozen cells were
thawed and transferred to a 15 mL tube with 9 mL of complete media: Filtered
HAM’s F-12, 1X (Modified) with L-glutamine (CORNING, Manassas, VA, USA)
supplemented with 10% fetal bovine serum (Atlanta Biologicals) and 1% antibiotic:
Penicillin-Streptomycin solution (Cellgro). After centrifugation at 125 x g for 5 min,
the cell pellet was re-suspended and seeded in a 25cm2 culture flask with 10 mL
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complete media. Cultures were incubated at 37°C with 5% CO2 atmospheric
conditions. Media was replaced every 48 h. When cells reached approximately 90%
confluence, they were subcultured in three 75cm2 culture flasks (BD FalconTM;
Bedford, MA). Cells from confluent cultures, passages 1 and 2, were cryopreserved
in complete medium and supplemented with 5% Dimethyl sulphoxide (DMSO;
Sigma-Aldrich; St. Louis, MO).

MTS Viability Assay
Assessment of cell viability for varying treatment levels of LPS and CLA were
performed with a CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay kit
(Promega; Madison, WI, USA) that utilizes 3-(4,5-dimethylthiazol-2-yl)-5(3carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) with phenazine
methyl sulfate (PMS). MTS assays were performed with LPS, CLA, controls, and
background wells, consisting of media only. Synoviocytes, cell line HIG-82, were
plated in triplicate at a density of 1.0 x 104 cells/well in a MICROTESTTM Tissue
Culture 96-well plate (FALCON®) with a flat bottom and low evaporation lid. Each
well contained 100μL complete media and the plate was incubated at 37°C with 5%
CO2 for 10 hours. The LPS was then added to wells at dosages of 5, 10, and 20
μg/mL: dosages were based on previous in-vitro studies using chondrocytes
(Haglund et al., 2008; Stadler et al., 1991). A total volume of 100 μL per well was
maintained by drawing off the corresponding amount of media and replacing with
LPS. Control wells contained 2 μL phosphate buffer solution and the background
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wells consisted of media only. The plate was then incubated at 37°C with 5% CO2
for 4 additional hs. Two h prior to completion of the assay, 20 μL MTS/PMS solution
(Sigma Aldrich; St. Louis, MO) was added to each well and returned to the incubator.
Upon completion of the assay, absorbance values were recorded at a wavelength of
490nm using a Bio-Tek plate reader and KC4 Program. Recorded optical density
(OD) values were utilized to form a stimulation index (SI), calculated by the ratio of
treatment OD: control OD.
The cytotoxic effect of CLA on HIG-82 was measured similarly with cells
plated in triplicate at the same density and allowed the same allotment of time
before treatment. However, 10 h after plating all media was drawn off and replaced
with CLA supplemented media, prepared as previously described, and treated for 10
h. The CLA concentrations of 10, 20, and 50 μM were tested and 100% ethanol
concentration was consistent throughout treatments. Control media lacked CLA.
The CLA dosage range was based on previous in-vitro studies performed with CLA
or other PUFAs (Falconer et al., 1994; Shen et al., 2004).

HIG-82 Treatment
Cells were stained with Trypan Blue Solution (0.4% w/v in normal saline;
Cellgro®) and viable cells counted on a Bright-Line Hemocytometer. The
synoviocytes were then seeded at a density of 6 x 105 cells/well in a Tissue Culture
Plate, 6-Well (FALCON®), with a flat bottom and low evaporation lid. Each plate
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contained duplicates of each treatment group. No cells beyond the fifth passage
were used.
Twelve hours after plating, media was replaced with fresh media containing
50 μM CLA. The CLA was dissolved in the medium with 100% ethanol, allowing
ethanol to serve as the cellular vehicle (40 mM; Shen et al. 2004), and an equal
amount of ethanol was added to the control media (0 μM CLA group). Ethanol
concentration used was based on a previously effective concentration (Shen et al.,
2004).
Twenty-four hours post CLA treatment, LPS was added separately to each
well at a concentration of 10 μg/mL. Selected cells were challenged with LPS for 4 h.

RNA Isolation
Following the commencement of the 4 h LPS-challenge the synoviocyte total
RNA was isolated from cell cultures using the PureLinkTM RNA Mini Kit (Ambion;
Austin, TX). Synoviocytes were lysed with 0.6 mL Lysis Buffer (PureLinkTM RNA Mini
Kit) containing 1% 2-mercaptoethanol on ice and were prepared for RNA isolation.
The lysate was transferred into a clean QIAshredderTM (Qiagen; Louisville, KY)
homogenization tube and centrifuged at 12,000 x g for 2 min. Following
homogenization, RNA was purified (according to the PureLinkTM RNA Mini Kit
protocol) and stored at -20°C until used for RT-PCR and qRT-PCR. The quality of all
RNA samples was analyzed using the NanoDrop 1000 Spectrophotometer (Thermo
Fisher Scientific; Wilmington, DE) for evaluation of concentration and purity. Based
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on the 260/280 and 260/230 ratios, the highest quality RNA sample was used for all
downstream applications. Total RNA concentration, 260/280, and 260/230 ratios
for all samples used in downstream applications can be found in Appendix A1.
A random subset of 4 RNA samples was chosen for further assessment of
quality. The integrity of the RNA was evaluated using the Agilent RNA 6000 Nano
Kit. Chips and reagents designed for the analyses of RNA fragments were included
in the kit and chips were evaluated on the Agilent 2100 Bioanalyzer (Agilent
Technologies; Santa Clara, CA). The assay class was a total Eukaryote Total RNA
Nano with nanogram sensitivity. The RNA chip contained an interconnected set of
microchannels that separate nucleic acid fragments. Fragments are separated by
size as they move through the chip electrophoretically. The results provide a RNA
Integrity Number (RIN) for each sample. Values for RIN can range from 1-10, with
10 being associated with highest integrity and quality.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Utilizing the two-step process, first strand cDNA was synthesized from 1 μg
total RNA using RETROscript® (Ambion; Austin, TX). The reverse transcriptase was
performed without heat denaturation in the Mastercycler gradient (Eppendorf;
Germany) at the following conditions: 1 h at 44°C and 10 min at 92°C.
Using 200 ng cDNA as template, polymerase chain reaction (PCR) was
carried out with 1 unit Taq DNA Polymerase (Recombinant; 5 U/μL; Invitrogen), 1X
PCR buffer, minus Mg++, 0.2 mM dNTP mixture, 1.5mM MgCl2, 25pmol/μL of gene
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specific primers. Nuclease-free water (QIAGEN Sciences; Maryland, USA) was used
to bring each reaction up to a volume of 50 μL. Amplification was performed in the
Mastercycler gradient (Eppendorf; Germany) with the following conditions: 3 min at
94 °C, 35 cycles of 45 s at 94 °C, 30 s at 60 °C, and 1.5 min at 72 °C, followed by final
extension at 72 °C for 10 min. Oligonucleotide primer sequences purchased from
Integrated DNA Technologies for both the protein of interest, cyclooxygenase-2
(Cox-2; 278 base pairs), and the internal positive control, glyceraldehyde 3phosphate dehydrogenase (GAPDH; 298 base pairs) are located in Table 2.

TABLE 2: HIG-82 Oligonucleotide primers for semi-quantitative RT-PCRa
Primer
GAPDH - Forward
GAPDH - Reverse
COX-2 – Forward
COX-2 - Reverse
aOligos

Sequence
Tm (°C)
5’-TCA CCA TCT TCC AGG AGC GA -3’
58.1
5’ -CAC AAT GCC GAA GTG GTC GT -3’
58.2
5’ -TCA GCC ACG CAG CAA ATC CT -3’
59.9
5’ –GTC ATC TGG ATG TCA GCA CG -3’
55.8

sequences based on literature (Lee et al., 2009)

Expression of both GAPDH and COX-2 mRNA were evaluated in end point
PCR. Gel electrophoresis was performed on 2% 40 mL agarose (United States
Biological; Swampscott, MA) gels were run at 92 v for 50 min. Gels were stained for
15 min in a 0.5 μg/mL EtBr (BioRad Laboratories; USA) solution with gentle
agitation. In order to reduce background, gels were destained in two 15-min gentle
agitation washes with nanopure water. Ultra-violet light was utilized to visualize
primer amplification. Gels were then photographed and saved digitally for later
analysis.
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RT-PCR Densitometry Analysis
The images from RT-PCR were analyzed using the imaging processing and
analysis software, ImageJ, from the National Institute of Health (Bethesda,
Maryland). ImageJ allowed for quantification of the amplified products using
densitometry. The images (.jpeg) were imported into the software, converted to
grayscale images, and bands were selected. The relative densities of each band were
plotted, with darker bands represented by higher peaks. The area under each peak
was measured and converted to a percentage density of all peaks for all bands of the
image. Then each percent value was divided by the control’s percent density
creating a relative density value for each band. The control was represented by a
value of one; proteins with increased expression had values greater than one and
decreased expression resulted in values below one. Adjusted relative density values
for COX-2 were normalized to the positive internal control, GAPDH.

Statistical Analysis
Analysis of Variance (ANOVA) was performed to evaluate the treatment
effect on all data collected from viability and RT-PCR densitometry assays using the
SAS GLM Procedure of the Statistical (SAS Inst., Research Triangle Park, NC). The
model for the ANOVA included terms for main effects and treatment effects of LPS,
CLA, LPS*CLA interaction, and plate. All data sets were plotted in box and whisker
plots for identification of outliers and examined for normality using the Proc
Univariate procedure in SAS. One plate contained multiple outliers, and as a result it
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was removed from the study making the total sample size n=20 with n=5 in each
treatment group. The LSMeans procedure was then used to determine statistical
significance among the four treatment groups. Significance was declared at P < 0.05
with a trend towards significance at P ≤ 0.10.
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CHAPTER 4
RESULTS
MTS Assay
The MTS assay was used to evaluate cytotoxic effects from treatments of LPS
and CLA. Neither LPS nor CLA were cytotoxic (>50% cell death) at the
concentrations tested for this study (Tables 2 and 3). The SI values were used to
help establish a starting concentration of LPS and CLA for dosage in treatments. The
SI demonstrates the effect of treatment when compared to the control. Values
higher than 1 indicate that the treatment is causing more cell death than the control
treatment. A lethal dose, killing off 50% of the cell population, would have an SI
value of 1.5. Because there were no cytotoxic effects at any concentration, we chose
the middle concentration of LPS to proceed. We felt it exhibited a large enough
negative affect to cause an adequate inflammatory response and was therefore a
good starting point for a preliminary study. The CLA concentration was chosen
based on which concentration had the smallest negative impact on the cells (lowest
SI). Concentrations chosen to proceed were 10 ng/mL LPS and 50 mM CLA.
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Table 3: Effects of LPS on cytotoxicity of synoviocytes in cell culture.

0 ng/mL
5 ng/mL
10 ng/mL
20 ng/mL

Avg. Optical
Density
0.3120
0.3550
0.3533
0.3485

Standard
Deviation
0.006
0.008
0.010
0.050

Background

0.1047

0.002

[LPS]

Stimulation
Index
1
1.1378
1.1325
1.0588

Cells were plated in triplicate on a 96-well plate. Each well had 100 μL complete
media and a cell density of 1.0 x 104 cells/well. Dosages of 5, 10, and 20 μg/mL LPS
were added to wells for 4 h. The plate was read at 490 nm and absorbance values
from each treatment were averaged to form the average optical density (OD). The
average OD values were used to form a stimulation index; values were calculated by
the ratio of treatment average OD: 0 ng/mL OD. Background measurements were
determined using wells containing only media.
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Table 4: Effects of CLA on cytotoxicity of synoviocytes in cell culture

0 μM
10 μM
20 μM
50 μM

Avg. Optical
Density
0.2983
0.3317
0.3267
0.2853

Standard
Deviation
0.021
0.044
0.032
0.010

Background

0.089

0.001

[CLA]

Stimulation
Index
1
1.1117
1.0950
0.9564

Cells were plated in triplicate on a 96-well plate. Each well had 100 μL complete
media and a cell density of 1.0 x 104 cells/well. Dosages of CLA were added to wells
at concentrations of 10, 20, and 50 mM for 10 h. The plate was read at 490 nm and
absorbance values from each treatment were averaged to form the average optical
density (OD). The average OD values were used to form a stimulation index; values
were calculated by the ratio of treatment average OD: 0 ng/mL OD. Background
measurements were determined using wells containing only media.
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RNA Integrity
The results of the Nano Kit analysis revealed optimal RIN values of 10 for all
four randomly selected RNA samples. Each sample displayed clean peaks at 18 s and
28 s intervals, demonstrating the RNA was not degraded and had a high integrity
(Figures 3 &4).

Figure 4: Electrophoresis of the 4 randomly selected RNA samples. Chip analysis
tested on the Agilent 2100 Bioanalyzer.
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Figure 5: Electropherograms of 4 randomly selected RNA samples. All samples
display clean peaks at 18 s and 28 s (respectively) and have RNA integrity values
(RIN) of 10. Fluorescence is on the y-axis and time is displayed on the x-axis.

Cox-2 mRNA Expression in HIG-82 Fibroblastic Synoviocytes
Analysis of variance (ANOVA) revealed an overall treatment effect (P = 0.03)
on Cox-2 mRNA expression, as assessed through RT-PCR. There were no differences
in data across all treatment plates (P = 0.15). The main effect of LPS treatment was
significant (P = 0.003); however, no main effect was identified for CLA (P = 0.286).
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There was also no treatment CLA*LPS interaction (P = 0.198). All ANOVA tables are
located in Appendix A4.
Comparisons of the four treatments, using LSmeans, were conducted and
adjusted relative density concentrations are displayed in Figure 5. When compared
to both the non-treated control and treatment with CLA only (24 h), pre-treatment
with CLA (50 mM) for 20 h before the 4-h challenge with LPS (10 mg/mL) caused up
regulation of Cox-2 mRNA expression in the synoviocytes (Control, P = 0.006 and
CLA, P = 0.004). Compared to the control, cells subjected only to the LPS challenge
tended to show an increase in expression of Cox-2 mRNA (P = 0.10). Synoviocytes
treated with CLA only tended to have a lower expression of COX-2 than cells that
underwent the LPS challenge (P = 0.10). Least Squared Means output is located in
Appendix A4.
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COX
COX-2 mRNA Expression
Adjusted Relative Density

1.08

b

1.06

ab

1.04
1.02

a

a

1
0.98
0.96
0.94
Control

CLA (50 mM)
LPS (10 mg/mL)
Treatment

CLA + LPS

Figure 6: COX-2
2 mRNA expression measured in HIG
HIG-82
82 synoviocytes treated with
no additive (control), 50 mM CLA, 10 mg/mL LPS, or both (CLA + LPS). The
duration
uration of CLA treatment was 24 h with the addition of LPS at 20 h.
abTreatments

with different letters are statisti
statistically different based on the ANOVA

followed by pairwise t-tests
tests (P < 0.05).
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CHAPTER 5
DISCUSSION

Previous studies have demonstrated CLA’s anti-inflammatory properties in
multiple tissues, but to our knowledge this is the first study to examine CLA’s effect
on fibroblastic synoviocytes. This preliminary study demonstrates that CLA and LPS
can be successfully supplemented to rabbit fibroblastic synoviocyte cultures
without inducing cellular death. Utilizing the MTS assay, both the effects of CLA and
LPS were examined individually. A lethal dose would have caused the death of half
of the cell population (LD50). All concentrations tested for both CLA and LPS
treatments caused less than 50% reduction of cell viability in synoviocyte cultures.
The dosages tested for this study were far from reaching the LD50, indicating there is
potential for future studies to vary the dosages of CLA and LPS.
The purpose of studying the effects of CLA and LPS on fibroblastic
synoviocytes was to determine if CLA supplementation could provide a protective
effect within the joint by mitigating or decreasing the inflammatory response.
Synovial fluid biomarkers such as cytokines, matrix metalloproteinases, insulin-like
growth factors, eicosanoids, and hyaluronic acid have been utilized to assist in the
detection of the onset and severity of joint disease in vivo (McIlwraith, 2005).
Bertone and colleagues (2001) reported PGE2 as a good to excellent marker of joint
disease in horses. The production of PGE2 by the synoviocytes is elicited by the
presence of the enzyme COX-2. The COX-2 enzyme is the primary enzyme initiating
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the AA cascade and is up regulated in inflamed tissues. Due to its involvement in
PGE2 production, we were interested in evaluating COX-2’s production by
synoviocytes, when exposed to LPS and CLA. We hypothesized that CLA
supplementation would provide a protective effect to the synoviocyte by decreasing
COX-2 production in an inflammatory-induced model. In doing so, the CLA
supplementation would indirectly decrease PGE2 production.
Hyaluronan solutions are hydrophilic and viscous, thus making it the primary
lubricating molecule in the synovial fluid (Todhunter, 1996; Jiang et al., 2007).
Fibroblastic synoviocytes are directly involved with the synthesis of hyaluronan
(Iwanaga et al., 2000). The molecular weight of hyaluronan molecules varies. This
variation in weight directly influences the water binding capacity of each molecule.
As a result, HMW hyaluronan is the predominate molecule present in the synovial
fluid (Noble, 2002). The substantial role of HMW hyaluronan plays in the joint
sparked our interest in the investigation of CLA’s and LPS’s effects on the synthesis
and degradation of HMW hyaluronan. The two enzymes responsible for HMW
hylauronan’s synthesis are HAS-2 and HYAL-2, respectively (Tanimoto et al., 2001;
Bastow et al., 2008). Unfortunately, due to inadequate primer sequences, we were
unable to gather these data. Re-evaluation of HYAL-2 and HAS-2 primer design is
the next step for this work.
This in-vitro study demonstrated that production of COX-2 by fibroblastic
synoviocytes tended to increase when stimulated with LPS producing a localized
inflammatory insult. When supplemented with CLA only, no effect on COX-2
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expression by the synoviocytes was observed. Contrary to what we hypothesized,
treatment of synoviocytes with CLA prior to addition of LPS prompted an increase in
synoviocytes’ COX-2 expression. This significant up-regulation of COX-2 mRNA
expression suggests a possible synergistic effect rather than a protective effect. This
indicates that the COX-2 pathway may not be the mechanism in which CLA regulates
inflammation in synoviocytes.
This preliminary study presents many directions for future in-vitro work to
proceed. Factors in this study may be utilized as a starting point for dosage, time,
and isomer effects.
Altering the dosage rates for both LPS and CLA would likely affect COX-2
expression. It is suspected that an increase in the dosage of LPS could initiate a
more dramatic inflammatory response with COX-2 expression increasing. With that
being said, there is a probability that an increase in dosage of CLA could also
potentially produce a different outcome. A study designed to evaluate dosage
effects of both LPS and CLA on synoviocytes would provide more insight. However,
one could argue that CLA dosage may not be the most important factor. It may be
that by allowing the CLA more time to incorporate into the cellular membranes the
effect CLA exerts on the cells would change. This addition of time of CLA treatment
prior to the LPS challenge would provide a better representation of CLA’s protective
effects. Therefore, investigating a time effect of CLA is another logical step.
Additionally, these cells underwent the LPS challenge for only 4 hours; this may not
have allotted enough time for the CLA to counteract the cellular response to the LPS.
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The isomers of CLA (cis-9, trans-11 and trans-10, cis-12) have been shown to
have distinct biological effects associated with each isomer and responses may also
be initiated and/or increased through synergistic action. We chose to utilize an
~50:50 ratio of isomers for better comparability to a collaborative in-vivo study.
Additionally the use of a 50:50 isomer mixture provides a solid starting point.
Observation of cis-9, trans-11 and trans-10, cis-12’s synergistic effects on
fibroblastic synoviocytes is important as most nutritional supplements on the
market today are isomer mixtures. Consequently, using a mixture prevents our
ability to attribute the results to one particular isomer. Designing a study looking at
the effects of the specific isomers and a mixture of isomers would allow us to better
understand the differential effects CLA can exert in the joint.
Other important factors to note about this study are that we did not serum
starve the synoviocytes before treatment with CLA and/or LPS and 100% ethanol
served as the cellular vehicle. The lack of serum starvation means the cells might
have been in different growth phases before treatments. Serum starving the cells is
a tool that can be used to allow cells from different passages to be more comparable.
Without use of this step, it can be assumed that cells in different growth phases may
respond differently. However, cells in the body are typically in different growth
phases, thus, one can argue that the lack of serum starvation makes the in-vitro
model more comparable to in-vivo studies. Our use of ethanol may have exerted a
negative effect on the cells. As seen in our MTS CLA assay, the control had a higher
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SI than did the chosen concentration of CLA. This is why maintaining a consistent
ethanol concentration across all medias is crucial.
In a collaborative in-vivo study conducted at Texas A&M University, 24
horses were randomly assigned to one of three dietary treatment groups (control,
low CLA, and high CLA; Bradbury, et al., 2014). The authors observed no influence
of CLA supplementation on synovial PGE2, when stimulated with LPS intra-articular
carpal injections. Although no overall dietary treatment effect was observed, greater
PGE2 production was noted in horses fed CLA with concentrations peaking at 6 and
12 hours post injection (Figure 6A). Interestingly, horses fed the low CLA diet had
increased levels of PGE2 when compared to those fed both the high CLA and the
control diet across all time points, except at 0 hours. It is important to note a similar
trend in the contralateral control knees injected with lactated ringer solution (LRS),
which displayed higher expression of PGE2 in horses fed CLA compared to controls
(Figure 6B).
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Figure 7: (Trt, P = 0.15; Time, P < 0.01; Trt*Time, P = 0.24) A: Mean synovial fluid
concentrations (pg/mL) of prostaglandin E2 (PGE2) over time (h) after intraintra
articular injection of 0.5 ng lipopolysaccharide (LPS; derived from Escherichia coli
055:B5). Treatments were 1% diet soybean oil (CON; n=6)
n=6),, 0.5% diet soybean oil
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with 0.5% diet CLA (LOW; n=5), and 1% diet CLA (HIGH; n=6). B: Mean synovial
fluid concentrations (pg/mL) PGE2 over time (h) after intra-articular injection of 0.8
mL sterile lactated Ringer’s solution in contralateral control carpus. Graphs from
Bradbury et al., 2014, with permission.

Based on data collected from our present in-vitro study and Bradbury et al.
(2014), it seems that supplementation of CLA and LPS together may be causing a
synergistic reaction. One possible explanation for this increased inflammatory
response may be attributed to the CLA isomer mixtures utilized in both studies.
Neither the current study nor the companion in-vivo work supplemented one
specific CLA isomer, but rather utilized an isomeric mixture. Although CLA has been
attributed to having multiple beneficial properties, many of these properties are
isomer specific. The trans-10, cis-12 CLA isomer has been shown to decrease
inflammatory cytokine profiles systemically in pigs (Zhao et al., 2004; Changua et al.,
2005) where other studies have shown this isomeric form to be pro-inflammatory.
Poirier and colleagues (2006) found that supplementation of trans-10, cis-12 CLA
isomer induced local inflammatory gene expression of IL-6 and TNF-α in white
adipose tissue of mice. However, they did not observe alerted profiles of circulating
IL-6 or TNF- α (Poirier, 2006), indicating another factor to consider when evaluating
tissue-specific responses to each CLA isomer.
Systemic supplementation may be eliciting different results in-vivo, similarly
to Zhao and others (2005) by affecting other tissues and the systemic cytokine
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profile. Fatty acids are incorporated into the tissues throughout the body in in-vivo
studies and may provide different responses when compared to in-vitro studies. The
cis-9, trans-11 isomer has consistently been shown to decrease inflammation in
multiple in-vitro studies (Luongo et al., 2003; Kelleher et al., 2005; Lee, 2008). If the
cis-10, trans-12 CLA isomer is creating a pro-inflammatory response, the
antagonistic effects on inflammation by the two isomers may be negating each
other, and providing a possible explanation for the up regulation of COX-2 and PGE2
rather than the inhibitory effect. It is difficult to assume the response can be
attributed to a specific isomer. Further research evaluating the effects of both the
cis-9, trans-11 CLA and trans-10, cis-12 CLA individually on the synovium tissues is
needed.
An additional mechanism that could be attributed to the up regulation of the
pro-inflammatory biomarkers, COX-2 and PGE2, is CLA’s dependence upon
peroxisome proliferator activated receptor gamma (PPARλ) activation. The antiinflammatory effects of the cis-9, trans-11 CLA isomer are often attributed to PPARλ
activation (Bassaganya-Riera et al., 2004). The presence of PPARλ negatively
regulates inflammation, where agonists of PPARλ inhibit inflammation and decrease
catabolic products in the joint (Fahmi et al., 2010). The cis-9, trans-11 CLA isomer
has been shown to be a strong agonist for PPARλ and increased its expression in
human pre-adipocytes (Brown et al., 2003). Conversely, Brown et al. (2003) found
the trans-10, cis-12 isomer decreased PPARλ expression. However, the trans 10, cis12 CLA isomer has still been shown to be a weak partial agonist of PPARλ (Kennedy
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et al., 2008). Both isomers have been shown to act as an inhibitor of liganddependent PPARλ activation (Brown et al., 2003; Kennedy et al., 2008) and this
mechanism may explain how CLA isomers are agonist for PPARλ. Alternatively, LPS
acts as an antagonist and reduces PPARλ expression. Supporting this concept,
Simonin and colleagues (2002) tested the effect of LPS on PPARλ expression in rat
fibroblastic synoviocytes and observed a decrease in the presence of PPARλ
(Simonin et al., 2002). Therefore, the COX-2 and PGE2 results of the current study
and Bradbury et al. (2014) may be associated to a possible connection between the
expression of PPARλ and CLA’s effect on synoviocyte inflammation. The down
regulation of PPARλ expression by LPS observed in previous studies could be
preventing the cis-9, trans-11 CLA isomer from exerting its anti-inflammatory
properties within the synovium. More research would be needed to confirm this
interaction.
In conclusion, our data suggest the possibility of a synergistic effect causing
increased inflammation in the synovium when supplemented with both CLA and
LPS. The mechanism by which this is happening is unknown but could be attributed
to the isomer mixtures being supplemented. The opposing roles of the cis-9, trans11 CLA and the trans-10, cis-12 CLA may be decreasing CLA’s effectiveness as an
anti-inflammatory supplement. Future research is needed to determine time,
dosage, and specific CLA isomers’ effect on fibroblastic synoviocytes and the
synovium. Additionally, the down regulation of PPARλ by LPS could be causing an
inhibitory effect on the cis-9, trans 11 CLA isomer. This decrease in a component

48

involved in the mechanism by which it exerts its anti-inflammatory effect, in
combination with the presence of a pro-inflammatory trans-10, cis-12 CLA isomer,
may explain why there was no reduction in joint inflammation. Additional research
evaluating the effect of supplementation on the synovium is required.
As previously mentioned, the effect of CLA on HAS2 and HYAL expression is
our next step for this study. Although CLA did not exert the effect originally
anticipated, there is still potential for its use as an anti-inflammatory supplement.
There is a possibility that CLA is affecting joint inflammation through a different
pathway; therefore, its affect on HAS2 and HYAL2 expression will be an interesting
mechanism to evaluate.
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APPENDIX A1: RNA concentration and ratios
Treatment

Plate

(ng/µL)

260/280

260/230

Control
LPS
CLA
CLA+LPS

1
1
1
1

186.78
174.89
163.30
162.41

2.13
2.14
2.15
2.14

1.96
1.88
1.89
2.07

Control
LPS
CLA
CLA+LPS

2
2
2
2

132.56
130.19
187.08
241.53

2.16
2.16
2.13
2.14

1.46
1.81
1.78
1.58

Control
LPS
CLA
CLA+LPS

3
3
3
3

168.69
253.11
244.24
271.99

2.13
2.11
2.10
2.07

1.84
2.09
1.97
1.99

Control
LPS
CLA
CLA+LPS

4
4
4
4

176.78
143.41
180.00
188.84

2.13
1.70
2.12
2.12

2.07
1.97
1.83
1.87

Control
LPS
CLA
CLA+LPS

5
5
5
5

207.09
455.04
189.61
232.35

2.10
2.05
2.15
2.12

2.12
2.08
1.48
1.70

Control
LPS
CLA
CLA+LPS

6
6
6
6

187.87
185.22
162.65
174.48

2.15
2.13
2.12
2.13

1.59
1.61
1.85
1.99
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APPENDIX A2: cDNA concentration and ratios
Treatment

Plate

(µg/mL)

260/280

260/230

LPS
CLA
Control
LPS+CLA

1
1
1
1

927.3
793.4
1322.7
852.9

1.67
1.67
1.71
1.67

2.04
2.04
2.21
2.05

CLA
Control
LPS
LPS+CLA

2
2
2
2

1402.3
841.9
986.7
844.6

1.69
1.65
1.55
1.54

2.13
1.95
1.84
1.80

LPS
CLA
Control
LPS+CLA

3
3
3
3

886.0
861.1
829.2
839.0

1.64
1.65
1.65
1.65

2.02
2.02
2.02
2.02

Control
CLA
LPS
LPS+CLA

4
4
4
4

1491.8
1001.8
932.7
886.3

1.68
1.63
1.6
1.65

2.12
2.03
1.98
2.05

Control
LPS
CLA
LPS+CLA

5
5
5
5

841.5
715.3
646.6
699.7

1.64
1.63
1.63
1.6

2.05
2.00
1.92
1.92

Control
LPS
CLA
LPS+CLA

6
6
6
6

2313.3
2106.8
2098.4
943.1

1.59
1.58
1.66
1.47

2.04
1.98
2.11
1.73
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APPENDIX A3: RT-PCR photos utilized for ImageJ analysis
Plate 1

Cox-2

GAPDH
Plate 2

Cox-2

GAPDH
Plate 3

Cox-2

GAPDH
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Plate 4

Cox-2

GAPDH
Plate 5

Cox-2

GAPDH
Plate 6

Cox-2

GAPDH
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Appendix A4: Statistical Output for COX-2

ANOVA: Overall treatment effect on COX-2 adjusted relative density
Source

DF

Model

7

Sum of
Mean
Squares
Square
0.01504194 0.00214885

Error

12

0.00737155 0.00061430

Corrected Total

19

0.02241349

F Value

Pr > F

3.50

0.0277

ANOVA: Effect of treatments on COX-2 adjusted relative density
Source

DF

LPS

1

Mean
Square
0.00809226 0.00809226

CLA

1

LPS*CLA
Plate

Type III SS

F Value

Pr > F

13.17

0.0035

0.00076580 0.00076508

1.25

0.2863

1

0.00113854 0.00113854

1.85

0.1984

4

0.00504605 0.00126151

2.05

0.1505

Least Square Means: Effect of treatment on COX-2 adjusted relative density
Treatment
Control

Density LSMeans
1.000000

95% Confidence Limits
0.975850
1.024150

CLA

0.997280

0.973130

1.021430

LPS

1.025140

1.000990

1.049290

Both

1.052600

1.028450

1.076750
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